SuperMap-Based Research on the Spread Situation and Visual Monitoring Platform of Major Health Events.

To present information on infectious diseases caused by viruses clearly and track the changes of data in real-time, data visualization can be used preferentially considering that it can identify problems behind data accurately. In this paper, based on the SuperMap Online platform and Tianditu, a national platform for common geospatial information services, a risk level map of infectious diseases distribution area is made by Web GIS and cartography. Meanwhile, the platform plays an important role in information collection, management, analysis, prevention and control, and release of measures when a major health event spreads. The method shows many advantages, such as various visualization means, ease to be published and shared, simple operation, and programming realization, which may be taken as technical references for solving the same type of visualization application problems. The research also facilitates the data visualization and monitoring of the spread of infectious diseases in major health events, and can effectively provide services for monitoring, decision-making, dispatching, and handling the spread of infectious diseases.

Corrigendum: Acute and subacute toxicity assessment of oxyclozanide in Wistar rats.

[This corrects the article DOI: 10.3389/fvets.2019.00294.].

Acute and Subacute Toxicity Assessment of Oxyclozanide in Wistar Rats.

Oxyclozanide is an effective anthelmintic and has shown good properties in other ways including anti-adenovirus, anti-biofilm, antifungal, and antibacterial activity. This study aimed to investigate the acute and subacute 28-days repeated dose oral toxicity of an oxyclozanide suspension in Wistar rats. A high oral lethal dose (LD50) of 3,707 mg/kg was observed in the acute toxicity test. During the 28-days time period, no obvious adverse effects or death were detected. Histopathological changes were observed in the heart, liver, and kidney of animals treated with high dose of oxyclozanide. Based on the hematological parameters, there were no statistical differences between the oxyclozanide-treated group and the control group. For biochemistry assays, ALP, AST, GLU, TBIL, GLO, TG, BUN, UA, LDH, and CK were statistically changed in the treatment groups. These data suggested that the LD50 of oxyclozanide was ~3,707 mg/kg body weight (BW), and the lowest observed adverse effect level (LOAEL) of oxyclozanide was at a dose of 74 mg/kg in rats.